Vext Science (TSE:VEXT)
:VEXT
Top Page
Vext Science
(VEXT)
Select Model
Select Model
Rating:59Neutral
Price Target:
C$0.30
▼(-5.31% Downside)
Action:ReiteratedDate:12/20/25
Vext Science's overall score is driven by positive technical momentum and earnings call insights, despite weak financial performance and valuation. Revenue growth and cash flow improvements are promising, but profitability challenges and market pressures in Arizona weigh heavily on the score.
Positive Factors
Retail expansion (Ohio)
Ohio retail expansion and proven drive-thru formats create a durable revenue engine. Increasing store count and convenience offerings raise customer frequency and geographic scale, diversifying revenue away from mature markets and supporting steady topline growth and unit economics over time.
Negative Factors
Negative profitability
Large negative net margin and negative EBIT show the company has yet to convert revenue growth into sustainable profits. Persistent operating losses erode equity, constrain reinvestment capacity, and require either structural margin improvement or ongoing external funding to support growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Retail expansion (Ohio)
Ohio retail expansion and proven drive-thru formats create a durable revenue engine. Increasing store count and convenience offerings raise customer frequency and geographic scale, diversifying revenue away from mature markets and supporting steady topline growth and unit economics over time.
Read all positive factors
Vext Science (VEXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$54.49M
Dividend YieldN/A
Average Volume (3M)40.05K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue Growth43.56%
EPS Growth-349.41%
CountryCA
Employees173
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding180,409,180
10 Day Avg. Volume23,955
30 Day Avg. Volume40,052
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)0.81
P/FCF Ratio15.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)C$67.87M
Vext Science Business Overview & Revenue Model
Company Description
Vext Science (VEXT) is a diversified cannabis company operating in the legal cannabis market, primarily focused on the production and sale of high-quality cannabis products. The company operates in multiple sectors, including cultivation, processi...
How the Company Makes Money
Vext Science generates revenue through several key streams, including the sale of its cannabis products directly to consumers via its retail outlets and through wholesale distribution to other dispensaries. The company capitalizes on its cultivati...
Vext Science Earnings Call Summary
Earnings Call Date:Nov 20, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth and positive cash flow, driven by retail expansion and yield improvements. However, challenges in the Arizona market and wholesale price pressures, along with permitting delays in Ohio, posed significant challenges.Positive Updates
Revenue Growth
Revenue for Q3 2025 was $12.7 million, up 41% year-over-year. Year-to-date revenue reached $37.6 million, up 46% from 2024, driven by expansion in Ohio and steady performance in Arizona.
Negative Updates
Arizona Market Challenges
Statewide sales in Arizona were down about 12% sequentially and 6% year-over-year due to pricing pressure and typical summer seasonality.
Read all updates
Q3-2025 Updates
Positive
Negative
Revenue Growth
Revenue for Q3 2025 was $12.7 million, up 41% year-over-year. Year-to-date revenue reached $37.6 million, up 46% from 2024, driven by expansion in Ohio and steady performance in Arizona.
Read all positive updates
Company Guidance
During the Vext Sciences Third Quarter 2025 Financial Results Conference Call, the company provided guidance reflecting a strong quarter with revenue reaching $12.7 million, a 41% increase year-over-year, driven by their operations in Ohio and Arizona. The company reported positive operating cash flow for the fourth consecutive quarter and an adjusted EBITDA of $2.1 million, representing a 16.7% margin. In Ohio, the retail expansion, including the opening of new dispensaries and the introduction of drive-thrus, contributed to steady revenue, while the mature Arizona market faced pricing pressures, impacting margins. Vext plans to open three additional dispensaries in Ohio by 2026, with improved cultivation yields expected to bolster revenue growth. The company remains focused on operational efficiency, cash generation, and a disciplined, capital-light strategy to support long-term growth and shareholder value.Vext Science Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.83M | 36.00M | 34.81M | 35.41M | 37.24M | 25.19M |
| Gross Profit | 13.25M | 8.98M | 12.04M | 23.10M | 18.69M | 11.20M |
| EBITDA | 6.17M | -2.02M | 16.77M | 15.03M | 12.80M | 5.52M |
| Net Income | -16.65M | -22.44M | 4.40M | 10.92M | 4.99M | 2.13M |
Balance Sheet | ||||||
| Total Assets | 128.09M | 136.97M | 149.56M | 120.52M | 83.70M | 55.45M |
| Cash, Cash Equivalents and Short-Term Investments | 3.70M | 4.62M | 8.72M | 5.93M | 6.47M | 1.75M |
| Total Debt | 35.06M | 39.52M | 38.60M | 38.15M | 14.10M | 11.49M |
| Total Liabilities | 59.68M | 61.23M | 54.58M | 48.60M | 24.31M | 19.14M |
| Stockholders Equity | 68.41M | 75.74M | 94.98M | 71.92M | 59.39M | 36.31M |
Cash Flow | ||||||
| Free Cash Flow | 9.04M | 1.82M | 1.69M | -2.94M | -7.10M | -964.90K |
| Operating Cash Flow | 12.53M | 3.29M | 4.42M | 5.92M | 11.68M | 3.10M |
| Investing Cash Flow | -5.59M | -5.44M | -4.82M | -30.31M | -27.10M | -12.90M |
| Financing Cash Flow | -6.08M | -1.95M | 3.19M | 23.86M | 20.14M | 4.26M |
Vext Science Technical Analysis
Negative
0.32
Price Trends
0.26
Negative
0.26
Negative
0.25
Negative
Market Momentum
>-0.01
Positive
36.09
Neutral
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VEXT, the sentiment is Negative. The current price of 0.32 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.26, and above the 200-day MA of 0.25, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.09 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VEXT.
Vext Science Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | C$54.49M | -6.17 | -21.73% | ― | 43.56% | -349.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$149.85M | -1.15 | -119.94% | ― | -4.23% | 37.33% | |
47 Neutral | C$62.35M | -1.02 | -66.52% | ― | 2.19% | -91.41% | |
46 Neutral | C$18.85M | -5.08 | -68.32% | ― | 2.41% | 74.61% | |
45 Neutral | C$61.23M | -3.62 | 163.84% | ― | ― | ― | |
45 Neutral | C$27.35M | -3.68 | -19.10% | ― | 18.06% | 34.58% |
* Healthcare Sector Average
TSE:VEXT
Vext Science
0.22
0.04
22.22%
TSE:LEEF
Leef Brands
0.23
0.03
15.00%
TSE:CWEB
Charlotte's Web Holdings
0.94
0.81
623.08%
TSE:LABS
MediPharm Labs
0.07
-0.04
-35.00%
TSE:PLTH
Planet 13 Holdings
0.19
-0.16
-45.71%
TSE:AVCN
Avicanna
0.15
-0.16
-50.82%
Vext Science Corporate Events
Other
Vext Insider Jason Nguyen Trims Controlling Stake and Partially Repays Company Debt
Neutral
Jan 2, 2026
Major shareholder Jason T. Nguyen has reduced his stake in Vext Science, Inc. following a share conversion and sale transaction that modestly diluted his ownership while leaving him as the controlling shareholder. Nguyen sold 20,340 Class A Multip...
Business Operations and StrategyFinancial Disclosures
Vext Science Reports Corrected Q3 2025 Financials with Strong Revenue Growth
Positive
Dec 16, 2025
Vext Science, Inc. reported corrected financial results for Q3 2025, revealing a revenue increase of 41% year-over-year to $12.7 million, driven by expanded operations in Ohio and steady performance in Arizona. Despite earlier inaccuracies in fina...
Business Operations and StrategyShareholder Meetings
Vext Science Secures Strong Shareholder Support at Annual Meeting
Positive
Dec 11, 2025
Vext Science, Inc. announced the successful voting results from its annual general meeting, with over 97% of votes cast in favor of all resolutions. This strong shareholder support reflects confidence in the company’s strategic direction and...
Business Operations and StrategyFinancial Disclosures
Vext Science Sees 41% Revenue Growth in Q3 2025 Amid Ohio Expansion
Positive
Nov 20, 2025
Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded operations in Ohio and strong performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5 million, a...
Business Operations and StrategyFinancial Disclosures
Vext Science Achieves 41% Revenue Growth in Q3 2025
Positive
Nov 20, 2025
Vext Science reported a 41% year-over-year increase in revenue for Q3 2025, reaching $12.7 million, driven by expanded retail operations in Ohio and consistent performance in Arizona. The company achieved a year-to-date operating cash flow of $8.5...
Financial Disclosures
Vext Science to Release Q3 2025 Financial Results on November 20
Neutral
Nov 11, 2025
Vext Science, Inc. announced it will release its Q3 2025 financial results on November 20, 2025, followed by a conference call and webcast to discuss the results. This announcement is significant as it provides stakeholders with insights into the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.